ArticleFrontiers in medicine2025
Investigating the risks of late preterm and term neonatal morbidity across clinical subtypes of intrahepatic cholestasis of pregnancy.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The influence of serum sterol sulfotransferase, ANGPTL8, and SDC1 on liver function in patients with intrahepatic cholestasis during pregnancy.Journal of medical biochemistry · 2026Article
- Intrahepatic Cholestasis of Pregnancy: Diagnosis, Management, and Future Directions-A Review of the Literature.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This investigation assesses the perinatal risks associated with different clinical subtypes of intrahepatic cholestasis of pregnancy (ICP) based on clinical symptomatology, with the goal of informing optimal delivery timing for each specific ICP subtype. Study design: The retrospective study encompassed 2,057 singleton pregnancies with ICP, categorized into the single-symptomatic (ICP-S) and the multisymptomatic (ICP-M) groups. The ICP-M group was further subdivided based on symptom combinations: elevated TBA with elevated transaminases (ICP-M Results: Baseline characteristics suggested Conclusion: Women with ICP-M experience elevated perinatal risks, including a higher risk of coexisting GDM, as well as increased risks of preterm birth and NICU admissions. Personalized clinical management, optimizing delivery timing based on clinical subtypes, and providing UDCA to improve neonatal outcomes during pregnancy are important measures worthy of attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.